Blue-grey hyperpigmentation in acne after vandetanib therapy and doxycycline use: A case report
| Autor: | Jonah W Perlmutter, Rachel C Cogan, Marni C Wiseman |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | SAGE Open Medical Case Reports, Vol 10 (2022) |
| Druh dokumentu: | article |
| ISSN: | 2050-313X 2050313X |
| DOI: | 10.1177/2050313X221086316 |
| Popis: | Vandetanib is an oral tyrosine kinase inhibitor with cutaneous adverse effects that include the development of acne. We present a patient who underwent vandetanib therapy for stage IV medullary thyroid cancer in conjunction with the use of doxycycline for acne that developed. After vandetanib use, blue-grey pigmentation developed in the acne on his face, chest, back, and arms, which darkened after the use of doxycycline. We review the literature to report that this blue-grey hyperpigmentation was likely vandetanib-induced but may have been the result of both drugs being used in combination. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|